Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
Vice Chairman,
"It has been my honor and pleasure to serve as board chair of
Under El-Hibri's leadership, Aptevo went public on the Nasdaq in
"Fuad's retirement marks a new chapter for Aptevo, as his chairmanship has spanned the life of our Company," said
"I am honored to have the confidence and support of my fellow board members and look forward to assuming the chairmanship of Aptevo on
It is expected that
About
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy and safety of its therapeutic candidates and potential use of any such candidates as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "optimism," "potential," "designed," "engineered," "breakthrough," "innovative," "innovation," "promising," "plans," "forecasts," "estimates," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in the
CONTACT:
Investors
Phone: +1 206-859-6629
Email: IR@apvo.com / Millerm@apvo.com
Media
Phone: +1 917-884-7378
Email: jabraham@jqapartners.com
SOURCE:
accesswire.com
https://www.accesswire.com/684910/Aptevo-Therapeutics-Board-Chairman-Fuad-El-Hibri-Announces-Retirement-Effective-April-1-2022